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Dexamethasone Intravitreal Implant Rescue Treatment for 
Bevacizumab Refractory Macular Edema Secondary to Branch 
Retinal Vein Occlusion
Kyou Ho Lee, Eui Chun Kang, Hyoung Jun Koh
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Purpose: To evaluate the prognostic factors and outcomes of dexamethasone intravitreal implant (DEX implant) 
for intravitreal bevacizumab refractory macular edema secondary to branch retinal vein occlusion (BRVO).
Methods: This was a retrospective, interventional case series. Medical records were reviewed, and a total of 
38 eyes that were treated with DEX implant for macular edema secondary to BRVO that did not respond to 
at least two consecutive intravitreal bevacizumab injections (IBIs) were included. Best-corrected visual acuity 
(BCVA), central subfield macular thickness, and central subfoveal choroidal thickness were evaluated at base-
line, 2 months, and 6 months after DEX implantation.
Results: Patients had undergone an average of 6.32 ± 4.66 prior IBI treatments. The average BCVA improved 
from 0.53 ± 0.26 to 0.41 ± 0.25 and 0.44 ± 0.23 logarithm of the minimal angle of resolution (logMAR) at 2 and 
6 months, respectively (p < 0.001). The average central subfield macular thickness was 504.00 ± 121.54 μm 
at baseline and changed to 293.21 ± 74.17 μm and 427.28 ± 119.57 μm at 2 and 6 months, respectively (p < 
0.001 and p = 0.002). Average central subfoveal choroidal thickness was 237.46 ± 92.21 μm at baseline and 
changed to 204.75 ± 74.74 μm and 226.86 ± 90.77 μm at 2 and 6 months, respectively (p < 0.001 and p = 0.455). 
Twenty-two eyes (58%) gained ≥0.1 logMAR at 2 months, while 16 eyes showed no improvement. Low BCVA 
at symptom presentation, low baseline BCVA, and shorter duration of macular edema were correlated with 
increased BCVA after treatment.
Conclusions: The DEX implant improves functional and anatomical outcomes for up to 6 months in about half 
of the patients treated with IBI refractory macular edema secondary to BRVO, particularly in patients with low 
initial and baseline BCVA.
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Retinal vein occlusion (RVO) is the second most com-
mon vascular retinopathy after diabetic retinopathy [1], 
and macular edema is the most frequent cause of visual im-
pairment in patients with branch retinal vein occlusion 
(BRVO) [2]. In RVO, macular edema develops in 5% to 15% 
of eyes over a 1-year period [3]. Based upon the Branch 
Vein Occlusion study [4], only one-third of the eyes with 
macular edema due to BRVO and visual acuity <20 / 40 
improved to better than 20 / 40 acuity during a 3-year fol-
low-up period. 
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The results of several studies have shown that laser pho-
tocoagulation [5], intravitreal triamcinolone acetonide [6], 
intravitreal anti-vascular endothelial growth factor (VEGF) 
[7,8], and dexamethasone intravitreal implants (DEX im-
plants) [9] can be beneficial for treating macular edema 
secondary to RVO. To date, administration of the an-
ti-VEGF compounds ranibizumab and af libercept have 
been reported to significantly improve visual acuity and 
reduce macular edema with relatively few complications 
[10-13]. Although it has not been used as a prescription 
treatment, another anti-VEGF, bevacizumab, has shown 
promising results, with improved visual acuity and a de-
crease in macular thickness [14]. Because of its low cost 
and similar effectiveness in other macular diseases [15], 
bevacizumab is also widely used for treating macular ede-
ma secondary to BRVO. 
More recently, a biodegradable dexamethasone intravit-
real implant 0.7 mg (Ozurdex; Allergan, Irvine, CA, USA), 
which is applied with a sustained delivery, has been shown 
to both reduce the risk of vision loss and increase the speed 
and incidence of visual improvement in eyes with macular 
edema secondary to RVO, with effects that were sustained 
for up to 6 months after a single injection [9,16]. Thus, an-
ti-VEGF and steroid implants are currently widely consid-
ered as first-line treatments for macular edema secondary 
to RVO.
However, macular edema may be persistent and recur 
repeatedly. Previous studies have shown that repeated an-
ti-VEGF treatments are often required to control macular 
edema, prevent vision loss, and increase the chance of vi-
sual improvement [12]. In many cases of permanent or re-
current macular edema despite repeated anti-VEGF injec-
tions, switching to another medication can be considered. 
However, the results of the DEX implant for intravitreal 
bevacizumab injections (IBIs) for refractory macular ede-
ma secondary to BRVO are not fully known. Therefore, 
the purpose of this study was to evaluate the efficacy of 
DEX implants and to investigate positive prognostic fac-
tors of DEX implants in treating macular edema secondary 
to BRVO refractory to IBI.
Materials and Methods
This retrospective study was approved by the institution-
al review board of Yonsei University, Seoul, South Korea. 
All study protocols adhered to the tenets of the Declaration 
of Helsinki. All patient data were collected from the De-
partment of Ophthalmology, Severance Hospital, and 
Gangnam Severance Hospital.
We reviewed the medical records of 38 eyes of 38 pa-
tients who were treated with the DEX implant for intravit-
real bevacizumab (1.25 mg/0.05 mL Avastin; Genentech, 
South San Francisco, CA, USA) for refractory macular 
edema secondary to BRVO that did not respond after at 
least two consecutive IBIs between January 2012 and De-
cember 2014. All subjects underwent a comprehensive 
ophthalmologic examination at the time of initial disease 
presentation and the beginning of the DEX implant treat-
ments, including initial f luorescein fundus angiography, 
best-corrected visual acuity (BCVA) determinations, dilat-
ed fundus examinations, fundus photography, and spectral 
domain optical coherence tomography (SD-OCT; Spectra-
lis OCT ver. 1.5.12.0, Heidelberg Engineering, Heidelberg, 
Germany). After the DEX implant, BCVA measurements, 
tonometry, slit-lamp biomicroscopy, a dilated fundus ex-
amination, and OCT were repeated at the 2 month and 6 
month follow-up visits. We designated patients who 
demonstrated an increase of 0.1 or more logarithm of the 
minimal angle of resolution (logMAR) BCVA as the re-
sponsive group, while the other patients were designated as 
the nonresponsive group at the 6-month follow-up visit. 
We also investigated subgroups to identify factors that cor-
related with response to DEX implant.
The inclusion criteria were as follows: (1) initially treated 
with two or more consecutive IBIs, (2) refractory to IBI, 
no improvement or worsening visual acuity, <150 μm re-
duction in central subfield macular thickness (CSMT), and 
CSMT >300 μm, and (3) followed-up for at least 6 months 
after DEX implantation. The following were used as exclu-
sion criteria: severe media opacity, previous vitreoretinal 
surgery, intraocular inflammation, and other disorders that 
may have inf luenced macular function (e.g., exudative 
age-related macular degeneration, proliferative diabetic 
retinopathy, and epiretinal membrane). Patients with a vi-
sual acuity worse than 20 / 400 were also excluded. 
The CSMT was defined as the mean retinal thickness of 
the 1 mm center, as described in the Early Treatment Dia-
betic Retinopathy Study [17]. Choroidal thickness was 
measured by enhanced depth imaging OCT, which was 
performed by positioning the objective lens of the Spectra-
lis OCT scanner close enough in proximity to invert the 
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image, as described in previous reports [18,19]. Central 
subfoveal choroidal thickness (CSCT), defined as the verti-
cal distance between the hyperref lective line of Bruch’s 
membrane and the outermost hyperref lective line of the 
chorioscleral interface at the fovea, was measured manual-
ly using the built-in caliber. We used data from horizontal 
line scans. If it was difficult to identify the outer choroid in 
its entirety, we chose 10 points at which the chorioscleral 
interface could be identified easily and created a segmen-
tation line. All image measurements were averaged and 
were performed by two independent observers (KHL and 
ECK) who were masked to the clinical information. The 
visual acuity measurements were converted to the log-
MAR for analyses.
Statistical analysis
Serial comparisons of the mean BCVA, CSMT, and 
CSCT were performed using paired t-test. Comparisons of 
the mean BCVA, CSMT, and, CSCT between the two sub-
groups (responsive and nonresponsive) were analyzed us-
ing the Wilcoxon signed-rank test. Pearson’s test was used 
to identify factors that correlated with visual gain. The 
statistical significance level was set as p < 0.05. All statisti-
cal analyses were performed using SPSS ver. 20.0 for Win-
dows (IBM Corp., Armonk, NY, USA). The p-values less 
than 0.05 were considered significant.
Results
Thirty-eight eyes from 38 patients were included in this 
study, which included 12 men and 26 women. The mean 
age was 67.76 ± 10.27 years. Twenty-five eyes (66%) were 
phakic at the time of the DEX implant. The duration of 
macular edema between initial presentation and DEX im-
plant was 22.45 ± 19.53 months. The number of previous 
anti-VEGF injections was 6.32 ± 4.66. The initial mean 
BCVA at the time of disease presentation was 0.66 ± 0.40 
logMAR, and the baseline mean BCVA was 0.53 ± 0.26 
logMAR at DEX implantation. The baseline CSMT and 
CSCT were 504.00 ± 121.54 μm and 237.46 ± 92.21 μm, re-
spectively. Previous grid and sector pan retinal photocoag-
ulation were performed on 3 (8%) and 7 (18%) eyes, re-
spectively (Table 1).
Comparison of BCVA, CSMT, and CSCT before and 
after DEX implantation
Mean logMAR BCVA at 2 months after DEX implanta-
tion significantly improved from 0.53 ± 0.26 to 0.41 ± 0.25 
( p < 0.01). The amount of visual gain decreased at 6 
months to 0.45 ± 0.23 logMAR, but it was still statistically 
significant compared to baseline (p < 0.01). Both CSMT 
and CSCT were decreased at 2 months after DEX implan-
tation from 504.00 ± 121.54 μm and 237.46 ± 92.21 μm to 
293.21 ± 74.17 μm and 204.75 ± 74.74 μm, respectively 
(both p < 0.001). Six months after DEX implantation, 
CSMT and CSCT were slightly increased to 427.28 ± 
119.57 μm and 226.86 ± 90.77 μm, respectively. CSMT was 
still significantly thinner than baseline values (p = 0.002), 
but CSCT was not (p = 0.455) (Fig. 1A and 1B). Low initial 
(p = 0.025) and baseline logMAR BCVA values (p = 0.028) 
were correlated with visual gain 2 months after DEX im-
plantation, but age, number of IBIs, initial CSMT, initial 
CSCT, and thickness change in CSMT and CSCT were not 
Table 1. Patient characteristics
Characteristics Value
Study eyes 38
Sex, male 12 (32)
Age (yr) 67.76 ± 10.27
Lens status
Phakic 25 (66)
ME duration before DEX implant (mon) 22.45 ± 19.53
No. of previous IBIs 6.32 ± 4.66
Initial BCVA (logMAR) 0.66 ± 0.40
Baseline BCVA (logMAR) 0.53 ± 0.26
Baseline CSMT (μm) 504.00 ± 121.54
Baseline CSCT (μm) 237.46 ± 92.21
Previous laser treatment
Grid laser 3 (8)
Sector PRP 7 (18)
Macular edema secondary to branch retinal vein occlusion refrac-
tory to IBI. Values are presented as number (%) or mean ± stan-
dard deviation. 
ME = macular edema; DEX implant = dexamethasone intravit-
real implant; IBI = intravitreal bevacizumab injection; BCVA = 
best-corrected visual acuity; logMAR = logarithm of the minimal 
angle of resolution; CSMT = central subfield macular thickness; 
CSCT = central subfoveal choroidal thickness; PRP = pan retinal 
photocoagulation.
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significantly associated with visual change.
Comparison between the responsive and nonrespon-
sive groups
Twenty-two eyes (58%) showed 0.1 or more logMAR 
BCVA improvement, while 16 eyes (42%) showed no 
change in BCVA or worsening BCVA. We divided the pa-
tients into a responsive group and a nonresponsive group 
according to this criterion. In the responsive group, the 
mean initial and baseline logMAR BCVA were signifi-
cantly higher than those in the nonresponsive group, 0.77 ± 
0.46 and 0.61 ± 0.24 compared to 0.49 ± 0.25 and 0.42 ± 
0.23 (p = 0.049 and p = 0.019), respectively. The duration 
of macular edema between symptom presentation and 
DEX implantation for the responsive group was shorter 
than that of the nonresponsive group, 18.55 ± 17.73 months 
for the responsive group and 27.81 ± 16.90 months for the 
nonresponsive group (p = 0.022). The number of IBIs be-
fore DEX implantation was smaller in the responsive 
Table 2. Responsive and nonresponsive group comparisons
Characteristics Responsive group Nonresponsive group p-value
No. of eyes 22 (58) 16 (42) -
Age (yr) 67.32 ± 10.15 68.38 ± 10.73 0.906
Sex, male 6 (27) 6 (38) 0.503
Duration of ME (mon) 18.55 ± 17.73 27.81 ± 16.90 0.022
Initial BCVA (logMAR) 0.77 ± 0.46 0.49 ± 0.25 0.049
Baseline BCVA (logMAR) 0.61 ± 0.24 0.42 ± 0.23 0.019
Baseline CSMT (μm) 507.53 ± 108.24 499.92 ± 139.78 0.872
Baseline CSCT (μm) 237.40 ± 71.36 237.53 ± 114.84 0.997
No. of previous IBIs 5.95 ± 5.46 6.81 ± 3.35 0.195
Previous grid laser 2 (9) 1 (6) 1
Previous sector PRP 4 (18) 3 (19) 0.981
Values are presented as number (%) or mean ± standard deviation.
ME = macular edema; BCVA = best-corrected visual acuity; logMAR = logarithm of the minimal angle of resolution; CSMT = central 
subfield macular thickness; CSCT = central subfoveal choroidal thickness; IBI = intravitreal bevacizumab injection; PRP = pan retinal 
photocoagulation.
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Fig. 1. Functional and anatomical outcomes of dexamethasone intravitreal implants. (A) BCVA change. (B) CSCT and CSMT change. 
BCVA = best-corrected visual acuity; logMAR = logarithm of the minimal angle of resolution; CSCT = central subfoveal choroidal 
thickness; CSMT = central subfield macular thickness. 
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group (5.95 ± 5.46 times) than in the nonresponsive group 
(6.81 ± 3.35 times), but the difference was not statistically 
significant (p = 0.195). Age, sex, and previous laser treat-
ment (grid laser or sector pan retinal photocoagulation) 
were not significantly different between the two groups 
(Table 2). 
CSMT and CSCT significantly improved 2 months after 
DEX implantation in both the responsive and nonrespon-
sive groups, but the amount of improvement decreased af-
ter 6 months. The mean CSMT changes were 220.40 ± 
125.86 μm and 199.69 ± 153.70 μm (p = 0.012 and p = 0.101), 
respectively, and the mean CSCT changes were 41.69 ± 
30.49 μm and 24.93 ± 24.41 μm (p = 0.005 and p = 0.552).
Adverse events
A notable increase in IOP (>10 mmHg from baseline) 
was noted in five eyes (13.1%), which were subsequently 
treated with topical antiglaucoma medication. No other 
complications, including endophthalmitis and retinal de-
tachment, were observed. Two cases showed notable cata-
ract progression and underwent cataract extraction 6 and 8 
months after DEX implantation. After a single DEX im-
plant, two eyes (5.26%) needed no additional treatment due 
to complete resolution of macular edema, which was con-
firmed by OCT, while the other eyes needed additional 
treatment such as IBI or the DEX implant.
Discussion
In the present study, a single DEX implant was associat-
ed with significant improvement of visual acuity in IBI re-
fractory macular edema attributable to BRVO. The mean 
BCVA improved to 0.12 logMAR at 2 months and 0.08 
logMAR at 6 months after the DEX implant, but the effi-
cacy was lower than previous studies that used a DEX im-
plant as a first treatment [9,16,20,21]. However, considering 
that our patients had long-standing disease with multiple 
IBIs or laser and clinical IBI refractory macular edema, 
there was still significant efficacy. 
Improvement in BCVA and anatomical change in macu-
lar edema likely resulted from the specific effect of dexa-
methasone, which has somewhat different effects from an-
ti-VEGF agents. The strong efficacy of anti-VEGF treatment 
indicates that VEGF plays an important role in the devel-
opment of macular edema due to RVO. However, various 
cytokines, including interleukin-6 [22,23] and interleu-
kin-8 [24], can also be an effective treatment for macular 
edema in RVO. It is possible that the cases of macular ede-
ma in our study population refractory to intravitreal an-
ti-VEGF injection involved pathological changes unrelated 
to VEGF. Furthermore, steroid injection can reduce inter-
leukin-6 [25,26] and interleukin-8 [26], levels, which can-
not be modulated by anti-VEGF therapy.
The CSMT and CSCT of all patients improved after 
DEX implantation. However, only about half of the pa-
tients (22 eyes, 58%) experienced a BCVA improvement 
greater than 0.1 logMAR. We separated patients into the 
nonresponsive group and responsive group according to 
visual gain of 0.1 or more logMAR BCVA. In the sub-
group analysis, low BCVA at the time of DEX implant, 
low BCVA at initial disease presentation, and shorter dura-
tion of macular edema were associated with responsive-
ness to the DEX implant. A small number of patients with 
previous IBIs also showed an association with DEX im-
plants, but this correlation was not statistically significant 
(p = 0.195). 
Recently, a study reported that CSCT in eyes with RVO 
was significantly greater than in normal contralateral eyes, 
and that CSCT decreased significantly after DEX implants 
[27]. That study also reported that improved visual acuity 
correlated with a decrease in CSCT after the DEX implant. 
These findings are consistent with our data showing that 
the DEX implant decreased CSCT, but we did not find any 
significant correlation between CSCT or CSMT and visual 
improvement.
In our study, the safety profile was consistent with the 
results of the phase III Geneva Clinical Trial [9,16], show-
ing no serious ocular or systemic adverse events during the 
follow-up period. The most frequent adverse event was an 
increase in IOP, which required a topical IOP-lowering 
medication; however, this was only necessary in a small 
number of patients. Previous studies have reported intrav-
itreal use of steroids for refractory macular edema second-
ary to RVO [28,29]. To the best of our knowledge, this is 
the first study to investigate the prognostic factors of DEX 
implant for bevacizumab refractory macular edema sec-
ondary to BRVO. However, there were some limitations to 
this study, specifically in the retrospective design. The 
number of anti-VEGF injections before DEX implantation 
was also not well controlled. 
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In conclusion, DEX implants were found to be beneficial 
for patients with IBI refractory macular edema secondary 
to BRVO. At 2 months after implantation, patients gained 
a mean 0.12 logMAR BCVA and demonstrated a marked 
reduction in macular edema that lasted for up to 6 months. 
Moreover, about half of the patients showed a greater than 
0.1 logMAR BCVA gain, with a mean of 0.20 ± 0.13 log-
MAR BCVA improvement, especially in patients with low 
initial baseline BCVA and a shorter duration of macular 
edema. In addition to a relatively convenient dosing sched-
ule, longer drug action period, and low cost with minimal 
complications, our study suggests that DEX implants can 
be a valid treatment for IBI refractory macular edema sec-
ondary to BRVO. Further studies that involve long-term 
results of DEX implants for IBI refractory macular edema, 
together with comparisons of other treatment options with 
large populations, are therefore warranted to determine 
optimal treatment approaches.
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